Details of the Drug Combinations

General Information of This Drug (ID: DMMWSUL)

Drug Name
Lomustine   DMMWSUL
Synonyms
Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea
Indication
Disease Entry ICD 11 Status REF
Brain cancer 2A00 Approved [1]
Central nervous system neoplasm N.A. Approved [2]
Primitive neuroectodermal tumor N.A. Approved [2]
Classic Hodgkin lymphoma N.A. Investigative [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

204 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Bortezomib + Lomustine DCYY4GB Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [3]
Bortezomib + Lomustine DCIHAP2 Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [3]
Bortezomib + Lomustine DCMNL2M Bortezomib Adenocarcinoma (Cell Line: HCT116) [3]
Bortezomib + Lomustine DCY1X2A Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Bortezomib + Lomustine DC1Y3K4 Bortezomib Mesothelioma (Cell Line: MSTO) [3]
Bortezomib + Lomustine DCPMEH5 Bortezomib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Bortezomib + Lomustine DCPBG0K Bortezomib Carcinoma (Cell Line: EFM192B) [4]
Bortezomib + Lomustine DCD3TSX Bortezomib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Bortezomib + Lomustine DCJ2T3M Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [4]
Dasatinib + Lomustine DC0ODQQ Dasatinib Adenocarcinoma (Cell Line: A427) [3]
Dasatinib + Lomustine DCGS4BW Dasatinib Amelanotic melanoma (Cell Line: A2058) [3]
Dasatinib + Lomustine DC16EWQ Dasatinib Germ cell tumour (Cell Line: PA1) [3]
Dasatinib + Lomustine DCDB22X Dasatinib Mesothelioma (Cell Line: MSTO) [3]
Dasatinib + Lomustine DCH22YG Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Dasatinib + Lomustine DCNYORB Dasatinib Prostate carcinoma (Cell Line: LNCAP) [3]
Dasatinib + Lomustine DCUS8SY Dasatinib Breast carcinoma (Cell Line: OCUBM) [4]
Erlotinib + Lomustine DCT0J3Z Erlotinib Mesothelioma (Cell Line: MSTO) [3]
Erlotinib + Lomustine DCQYS1B Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Erlotinib + Lomustine DCL33KA Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Erlotinib + Lomustine DCK71ZE Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Erlotinib + Lomustine DCOMJPI Erlotinib Breast carcinoma (Cell Line: OCUBM) [4]
Fluorouracil + Lomustine DC758DG Fluorouracil Amelanotic melanoma (Cell Line: A2058) [5]
Fluorouracil + Lomustine DCYE3G3 Fluorouracil Mesothelioma (Cell Line: MSTO) [5]
Fluorouracil + Lomustine DCPHRJD Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Fluorouracil + Lomustine DCCQE92 Fluorouracil Prostate carcinoma (Cell Line: LNCAP) [5]
GSK525762 + Lomustine DC2TT9H GSK525762 Breast carcinoma (Cell Line: OCUBM) [4]
GSK525762 + Lomustine DC3GETX GSK525762 Adenocarcinoma (Cell Line: HCT116) [5]
GSK525762 + Lomustine DCGJ5EZ GSK525762 Mesothelioma (Cell Line: MSTO) [5]
GSK525762 + Lomustine DCA7CLG GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Idarubicin + Lomustine DC0UPSE Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [5]
Idarubicin + Lomustine DCQKNQ3 Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [5]
Idarubicin + Lomustine DCE08FW Idarubicin Mesothelioma (Cell Line: MSTO) [5]
Idarubicin + Lomustine DCG714U Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lapatinib + Lomustine DCXQM7K Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
Lapatinib + Lomustine DCYLA46 Lapatinib Breast carcinoma (Cell Line: OCUBM) [4]
Lapatinib + Lomustine DC656PZ Lapatinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Lapatinib + Lomustine DC2KT12 Lapatinib Amelanotic melanoma (Cell Line: A2058) [5]
Lapatinib + Lomustine DCD3DHX Lapatinib Mesothelioma (Cell Line: MSTO) [5]
Lapatinib + Lomustine DC6WTUA Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lomustine + Idarubicin DCHSVL1 Idarubicin Glioblastoma? (Cell Line: T98G) [3]
Lomustine + SCH-900776 DC3YOTX SCH-900776 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
Lomustine + SCH-900776 DCGKLP4 SCH-900776 Breast carcinoma (Cell Line: KPL1) [4]
Lomustine + SCH-900776 DCK0390 SCH-900776 Breast carcinoma (Cell Line: OCUBM) [4]
Lomustine + SCH-900776 DCMFRHQ SCH-900776 Colon carcinoma (Cell Line: RKO) [4]
Lomustine + Ridaforolimus DCJ5MMV Ridaforolimus Breast carcinoma (Cell Line: KPL1) [4]
Lomustine + Ridaforolimus DCO3F1D Ridaforolimus Breast carcinoma (Cell Line: OCUBM) [4]
Lomustine + Ridaforolimus DCPBPVS Ridaforolimus Colon carcinoma (Cell Line: RKO) [4]
Lomustine + SCH-900776 DC3BV33 SCH-900776 Adenocarcinoma (Cell Line: CAOV3) [5]
Lomustine + SCH-900776 DC2EPM7 SCH-900776 Adenocarcinoma (Cell Line: A427) [5]
Lomustine + SCH-900776 DC1BEJC SCH-900776 Adenocarcinoma (Cell Line: NCIH1650) [5]
Lomustine + SCH-900776 DCN2YBN SCH-900776 Adenocarcinoma (Cell Line: NCIH2122) [5]
Lomustine + SCH-900776 DC45KXH SCH-900776 Adenocarcinoma (Cell Line: NCIH23) [5]
Lomustine + SCH-900776 DCX4JWN SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [5]
Lomustine + SCH-900776 DCEUH1X SCH-900776 Adenocarcinoma (Cell Line: HCT116) [5]
Lomustine + SCH-900776 DC64ASW SCH-900776 Adenocarcinoma (Cell Line: HT29) [5]
Lomustine + SCH-900776 DCUFNLS SCH-900776 Amelanotic melanoma (Cell Line: A2058) [5]
Lomustine + SCH-900776 DCPQB8U SCH-900776 Malignant melanoma (Cell Line: A375) [5]
Lomustine + SCH-900776 DCMPILU SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [5]
Lomustine + SCH-900776 DCE774H SCH-900776 Malignant melanoma (Cell Line: SKMEL30) [5]
Lomustine + SCH-900776 DCVOQCN SCH-900776 Mesothelioma (Cell Line: MSTO) [5]
Lomustine + SCH-900776 DCYWW4F SCH-900776 Non small cell carcinoma (Cell Line: SKMES1) [5]
Lomustine + SCH-900776 DCX0734 SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lomustine + SCH-900776 DC2VN67 SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Lomustine + SCH-900776 DCZGVUP SCH-900776 Prostate carcinoma (Cell Line: LNCAP) [5]
Lomustine + Ridaforolimus DCIQZ2T Ridaforolimus Adenocarcinoma (Cell Line: CAOV3) [5]
Lomustine + Ridaforolimus DCLVZUS Ridaforolimus Adenocarcinoma (Cell Line: NCIH1650) [5]
Lomustine + Ridaforolimus DCB4U8H Ridaforolimus Adenocarcinoma (Cell Line: HCT116) [5]
Lomustine + Ridaforolimus DC8NI0N Ridaforolimus Malignant melanoma (Cell Line: RPMI7951) [5]
Lomustine + Ridaforolimus DCGZL57 Ridaforolimus Malignant melanoma (Cell Line: UACC62) [5]
Lomustine + Ridaforolimus DC9OWTB Ridaforolimus Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lomustine + Ridaforolimus DCGTO8K Ridaforolimus Prostate carcinoma (Cell Line: LNCAP) [5]
Lomustine + Ridaforolimus DCIYAZO Ridaforolimus Prostate carcinoma (Cell Line: VCAP) [5]
Lomustine + Sorafenib DC1WPO8 Sorafenib Mesothelioma (Cell Line: MSTO) [5]
Lomustine + Sorafenib DCW9FCW Sorafenib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
Lomustine + Sorafenib DC08EY2 Sorafenib Prostate carcinoma (Cell Line: LNCAP) [5]
MK-1775 + Lomustine DC66PPQ MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-1775 + Lomustine DCVCRTV MK-1775 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-1775 + Lomustine DCCR8BU MK-1775 Adenocarcinoma (Cell Line: HCT116) [3]
MK-1775 + Lomustine DCVLUHK MK-1775 Adenocarcinoma (Cell Line: HT29) [3]
MK-1775 + Lomustine DCPEGKM MK-1775 Adenocarcinoma (Cell Line: SW-620) [3]
MK-1775 + Lomustine DCATC9J MK-1775 Amelanotic melanoma (Cell Line: A2058) [3]
MK-1775 + Lomustine DC3TO8I MK-1775 Malignant melanoma (Cell Line: A375) [3]
MK-1775 + Lomustine DCUFY1O MK-1775 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-1775 + Lomustine DC0R7FE MK-1775 Mesothelioma (Cell Line: MSTO) [3]
MK-1775 + Lomustine DC68WMK MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-1775 + Lomustine DC23GGY MK-1775 Prostate carcinoma (Cell Line: LNCAP) [3]
MK-1775 + Lomustine DCX8T8L MK-1775 Prostate carcinoma (Cell Line: VCAP) [3]
MK-1775 + Lomustine DCUP87O MK-1775 Breast carcinoma (Cell Line: KPL1) [4]
MK-1775 + Lomustine DC496QF MK-1775 Breast carcinoma (Cell Line: OCUBM) [4]
MK-1775 + Lomustine DCQLKJA MK-1775 Carcinoma (Cell Line: EFM192B) [4]
MK-1775 + Lomustine DCDDTV0 MK-1775 Colon carcinoma (Cell Line: RKO) [4]
MK-2206 + Lomustine DC4QFN8 MK-2206 Amelanotic melanoma (Cell Line: A2058) [3]
MK-2206 + Lomustine DCTJLH7 MK-2206 Mesothelioma (Cell Line: MSTO) [3]
MK-2206 + Lomustine DCPVAWX MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-2206 + Lomustine DCJHRYM MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-4827 + Lomustine DCIAR1N MK-4827 Breast carcinoma (Cell Line: KPL1) [4]
MK-4827 + Lomustine DCJLCYS MK-4827 Breast carcinoma (Cell Line: OCUBM) [4]
MK-4827 + Lomustine DCO4EYL MK-4827 Adenocarcinoma (Cell Line: A427) [5]
MK-4827 + Lomustine DCQ2W8I MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-4827 + Lomustine DCTX38O MK-4827 Adenocarcinoma (Cell Line: HCT116) [5]
MK-4827 + Lomustine DC4N6KT MK-4827 Amelanotic melanoma (Cell Line: A2058) [5]
MK-4827 + Lomustine DCFHQT6 MK-4827 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-4827 + Lomustine DCI5OIV MK-4827 Mesothelioma (Cell Line: MSTO) [5]
MK-4827 + Lomustine DCPHRAI MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-4827 + Lomustine DCLAI9Q MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-4827 + Lomustine DCMN5NA MK-4827 Prostate carcinoma (Cell Line: LNCAP) [5]
MK-4827 + Lomustine DCQYX7M MK-4827 Prostate carcinoma (Cell Line: VCAP) [5]
MK-5108 + Lomustine DCD6M7Z MK-5108 Breast carcinoma (Cell Line: OCUBM) [4]
MK-5108 + Lomustine DC1J1GH MK-5108 Colon carcinoma (Cell Line: RKO) [4]
MK-5108 + Lomustine DCTQGNK MK-5108 Adenocarcinoma (Cell Line: CAOV3) [5]
MK-5108 + Lomustine DCLL8FP MK-5108 Adenocarcinoma (Cell Line: OVCAR3) [5]
MK-5108 + Lomustine DCFA2UY MK-5108 Adenocarcinoma (Cell Line: NCIH23) [5]
MK-5108 + Lomustine DCYIDWC MK-5108 Adenocarcinoma (Cell Line: COLO320DM) [5]
MK-5108 + Lomustine DCPJLJD MK-5108 Adenocarcinoma (Cell Line: HCT116) [5]
MK-5108 + Lomustine DC2FWLJ MK-5108 Adenocarcinoma (Cell Line: HT29) [5]
MK-5108 + Lomustine DCTSM72 MK-5108 Adenocarcinoma (Cell Line: SW-620) [5]
MK-5108 + Lomustine DCE5G6U MK-5108 Germ cell tumour (Cell Line: PA1) [5]
MK-5108 + Lomustine DC71E68 MK-5108 Malignant melanoma (Cell Line: RPMI7951) [5]
MK-5108 + Lomustine DCXOI1H MK-5108 Malignant melanoma (Cell Line: SKMEL30) [5]
MK-5108 + Lomustine DCLNHEK MK-5108 Mesothelioma (Cell Line: MSTO) [5]
MK-5108 + Lomustine DC1F6QV MK-5108 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
MK-5108 + Lomustine DCGF0MN MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
MK-5108 + Lomustine DCT3SNE MK-5108 Prostate carcinoma (Cell Line: LNCAP) [5]
PD-0325901 + Lomustine DCTIPEI PD-0325901 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PD-0325901 + Lomustine DCR43TM PD-0325901 Breast carcinoma (Cell Line: KPL1) [4]
PD-0325901 + Lomustine DCQZSFA PD-0325901 Breast carcinoma (Cell Line: OCUBM) [4]
PD-0325901 + Lomustine DC0WKM8 PD-0325901 Carcinoma (Cell Line: EFM192B) [4]
PD-0325901 + Lomustine DCBVC8K PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [4]
PD-0325901 + Lomustine DCZLEPN PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [5]
PD-0325901 + Lomustine DCONEFB PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [5]
PD-0325901 + Lomustine DCCWQLL PD-0325901 Adenocarcinoma (Cell Line: DLD1) [5]
PD-0325901 + Lomustine DCV0LO7 PD-0325901 Adenocarcinoma (Cell Line: HCT116) [5]
PD-0325901 + Lomustine DCEB44G PD-0325901 Amelanotic melanoma (Cell Line: A2058) [5]
PD-0325901 + Lomustine DCSXML4 PD-0325901 Germ cell tumour (Cell Line: PA1) [5]
PD-0325901 + Lomustine DCA7M07 PD-0325901 Malignant melanoma (Cell Line: HT144) [5]
PD-0325901 + Lomustine DCXJ05J PD-0325901 Malignant melanoma (Cell Line: RPMI7951) [5]
PD-0325901 + Lomustine DCOYUMY PD-0325901 Mesothelioma (Cell Line: MSTO) [5]
PD-0325901 + Lomustine DC5S7V4 PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
PD-0325901 + Lomustine DCKC0C4 PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [5]
PMID28460551-Compound-2 + Lomustine DCP4IKN PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HT29) [3]
PMID28460551-Compound-2 + Lomustine DCLPSEM PMID28460551-Compound-2 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
PMID28460551-Compound-2 + Lomustine DCZKRAH PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
PMID28460551-Compound-2 + Lomustine DCODSK4 PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
PMID28460551-Compound-2 + Lomustine DCM7GCZ PMID28460551-Compound-2 Breast carcinoma (Cell Line: ZR751) [4]
PMID28460551-Compound-2 + Lomustine DCLKOEG PMID28460551-Compound-2 Carcinoma (Cell Line: OV90) [4]
PMID28460551-Compound-2 + Lomustine DC6SZDS PMID28460551-Compound-2 Carcinoma (Cell Line: EFM192B) [4]
PMID28460551-Compound-2 + Lomustine DCC75ZS PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [4]
PMID28460551-Compound-2 + Lomustine DCG8UMB PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH1650) [5]
PMID28460551-Compound-2 + Lomustine DC17M64 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH2122) [5]
PMID28460551-Compound-2 + Lomustine DCV8W9G PMID28460551-Compound-2 Adenocarcinoma (Cell Line: NCIH520) [5]
PMID28460551-Compound-2 + Lomustine DCL3ZIC PMID28460551-Compound-2 Adenocarcinoma (Cell Line: HCT116) [5]
PMID28460551-Compound-2 + Lomustine DCENZ49 PMID28460551-Compound-2 Adenocarcinoma (Cell Line: SW-620) [5]
PMID28460551-Compound-2 + Lomustine DC9XZHG PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: A2058) [5]
PMID28460551-Compound-2 + Lomustine DCI6W22 PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [5]
PMID28460551-Compound-2 + Lomustine DCM57OR PMID28460551-Compound-2 Malignant melanoma (Cell Line: UACC62) [5]
PMID28460551-Compound-2 + Lomustine DCSMDQB PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [5]
PMID28460551-Compound-2 + Lomustine DCC7IHM PMID28460551-Compound-2 Non small cell carcinoma (Cell Line: SKMES1) [5]
PMID28460551-Compound-2 + Lomustine DC006ZU PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
PMID28460551-Compound-2 + Lomustine DCR8ABU PMID28460551-Compound-2 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
PMID28460551-Compound-2 + Lomustine DCIWOTK PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [5]
PMID28460551-Compound-2 + Lomustine DCKEAJB PMID28460551-Compound-2 Prostate carcinoma (Cell Line: VCAP) [5]
RTB101 + Lomustine DCJ9XJF RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
RTB101 + Lomustine DCGNUZG RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [4]
RTB101 + Lomustine DCGS356 RTB101 Breast carcinoma (Cell Line: KPL1) [4]
RTB101 + Lomustine DCO1OM9 RTB101 Breast carcinoma (Cell Line: OCUBM) [4]
RTB101 + Lomustine DCY6OHD RTB101 Carcinoma (Cell Line: EFM192B) [4]
RTB101 + Lomustine DC2NKIV RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [4]
RTB101 + Lomustine DCUVNIS RTB101 Adenocarcinoma (Cell Line: CAOV3) [5]
RTB101 + Lomustine DCJBKUL RTB101 Adenocarcinoma (Cell Line: A427) [5]
RTB101 + Lomustine DCBGLHP RTB101 Adenocarcinoma (Cell Line: NCIH2122) [5]
RTB101 + Lomustine DC2GJI8 RTB101 Adenocarcinoma (Cell Line: NCIH520) [5]
RTB101 + Lomustine DC94XDY RTB101 Adenocarcinoma (Cell Line: COLO320DM) [5]
RTB101 + Lomustine DCB2JM4 RTB101 Adenocarcinoma (Cell Line: DLD1) [5]
RTB101 + Lomustine DCYJRRX RTB101 Adenocarcinoma (Cell Line: HCT116) [5]
RTB101 + Lomustine DCRYRK1 RTB101 Adenocarcinoma (Cell Line: HT29) [5]
RTB101 + Lomustine DCYYCYP RTB101 Amelanotic melanoma (Cell Line: A2058) [5]
RTB101 + Lomustine DCRT4O2 RTB101 Malignant melanoma (Cell Line: A375) [5]
RTB101 + Lomustine DCVXHTC RTB101 Malignant melanoma (Cell Line: RPMI7951) [5]
RTB101 + Lomustine DCOY5B0 RTB101 Malignant melanoma (Cell Line: SKMEL30) [5]
RTB101 + Lomustine DCYT66Q RTB101 Malignant melanoma (Cell Line: UACC62) [5]
RTB101 + Lomustine DCFN2Z9 RTB101 Mesothelioma (Cell Line: MSTO) [5]
RTB101 + Lomustine DCJSEFX RTB101 Non small cell carcinoma (Cell Line: SKMES1) [5]
RTB101 + Lomustine DC3NJT4 RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
RTB101 + Lomustine DCEWYXO RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
RTB101 + Lomustine DC4UA5G RTB101 Prostate carcinoma (Cell Line: VCAP) [5]
SCH 727965 + Lomustine DCJFFUH SCH 727965 Breast carcinoma (Cell Line: OCUBM) [4]
SCH 727965 + Lomustine DCSWLF6 SCH 727965 Adenocarcinoma (Cell Line: NCIH2122) [5]
SCH 727965 + Lomustine DCDEF6R SCH 727965 Adenocarcinoma (Cell Line: HT29) [5]
SCH 727965 + Lomustine DCS1LNE SCH 727965 Amelanotic melanoma (Cell Line: A2058) [5]
SCH 727965 + Lomustine DC33CRL SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
SCH 727965 + Lomustine DCTL9GX SCH 727965 Prostate carcinoma (Cell Line: LNCAP) [5]
SCH 727965 + Lomustine DCFX1NM SCH 727965 Prostate carcinoma (Cell Line: VCAP) [5]
SNX-2112 + Lomustine DC891HL SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [4]
SNX-2112 + Lomustine DCZUIVN SNX-2112 Breast carcinoma (Cell Line: OCUBM) [4]
SNX-2112 + Lomustine DCR784D SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [4]
SNX-2112 + Lomustine DC8CCTB SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [5]
SNX-2112 + Lomustine DCSWL8L SNX-2112 Adenocarcinoma (Cell Line: DLD1) [5]
SNX-2112 + Lomustine DCTGYZ1 SNX-2112 Adenocarcinoma (Cell Line: HCT116) [5]
SNX-2112 + Lomustine DCVRFLD SNX-2112 Amelanotic melanoma (Cell Line: A2058) [5]
SNX-2112 + Lomustine DCMAJJO SNX-2112 Malignant melanoma (Cell Line: SKMEL30) [5]
SNX-2112 + Lomustine DCS3PQY SNX-2112 Mesothelioma (Cell Line: MSTO) [5]
SNX-2112 + Lomustine DCW9LN8 SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [5]
SNX-2112 + Lomustine DC7DPJ7 SNX-2112 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [5]
SNX-2112 + Lomustine DC5POBB SNX-2112 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 204 DrugCom(s)
11 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Buparlisib + Lomustine DCNJSM4 Buparlisib Recurrent Glioblastoma Multiforme [6]
Lomustine + DTI-015 DCA70XC DTI-015 Brain and Central Nervous System Tumors [7]
Lomustine + LY2157299 DCEAF6A LY2157299 Glioblastoma [8]
Lomustine + Cediranib DCUBRSD Cediranib Recurrent Glioblastoma [9]
Lomustine + DTI-015 DCV5KDL DTI-015 Glioblastoma Multiforme [10]
Selinexor + Lomustine DC8H0S7 Selinexor Glioblastoma Multiforme [11]
Temozolomide + Lomustine DCI6LII Temozolomide Brain Tumor [12]
Disulfiram + Lomustine DCLKDNQ Disulfiram Glioma [13]
Temozolomide + Lomustine DC2FA3A Temozolomide Glioblastoma Multiforme [14]
Eflornithine + Lomustine DCODY56 Eflornithine Anaplastic Astrocytoma [15]
Temozolomide + Lomustine DCVSNPC Temozolomide Anaplastic Astrocytoma [16]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7214).
2 Lomustine FDA Label
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6 ClinicalTrials.gov (NCT01934361) Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
7 ClinicalTrials.gov (NCT00004259) Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
8 ClinicalTrials.gov (NCT01582269) A Study in Recurrent Glioblastoma (GB)
9 ClinicalTrials.gov (NCT00503204) Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
10 ClinicalTrials.gov (NCT03382977) Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects. U.S. National Institutes of Health.
11 ClinicalTrials.gov (NCT04421378) A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
12 ClinicalTrials.gov (NCT00006024) Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
13 ClinicalTrials.gov (NCT02678975) Disulfiram in Recurrent Glioblastoma
14 ClinicalTrials.gov (NCT02414165) P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA. U.S. National Institutes of Health.
15 ClinicalTrials.gov (NCT02796261) Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
16 ClinicalTrials.gov (NCT00761280) Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma. U.S. National Institutes of Health.